Forget stock picking and market timing—Buffett’s 2026 guidance is clear: automate, diversify, and focus on long-term growth. By combining a broad S&P 500 fund, a value-focused ETF, and a high-dividend income fund, investors can replicate the strategy that has consistently outperformed hedge funds for decades. Simple, disciplined, and highly effective.

The final part breaks down precise allocations by age and savings stage, showing how even modest investments can compound into impressive wealth. The message is simple: extraordinary results come from ordinary, consistent actions—and these three ETFs are your foundation.

Let’s embark on this transformative journey together and position your portfolio for success in this evolving market landscape!

Be sure to read through to the end to catch all the valuable insights this newsletter delivers to your inbox today.

Picture this: Five years ago, the Financial Select Sector SPDR Fund $XLF ( ▲ 0.12% ) traded around $34–$35 per share. Today, it closes at $49.08 — a solid +43% gain. The chart shows a clear recovery from mid-period dips, with consistent upward movement in recent years as banks benefited from higher interest rates and economic stability.

The 52-week high reached $56.51, proving the ETF has already pushed higher during favorable banking conditions.

Keeping it simple: The compound annual growth rate (CAGR) over these five years is about 7.4%. If this pace continues, it means reliable yearly progress that builds gradually through compounding.

Every year, $240B is spent on treating the symptoms of osteoarthritis. But not a single therapy has been able to actually stop it. The answer, it turns out, has been inside us all along.

A startup named Cytonics discovered the human body already produces a protein designed to protect cartilage. It just doesn’t produce enough where it's needed most. So Cytonics harnessed it. 

Their first-generation therapy has already treated 10,000+ patients. Now they've engineered a 200% more potent, mass-producible version pushing toward FDA approval.

If approved, it could be the first therapy to actually halt cartilage destruction and promote regrowth in a market that has never had a real solution. Claim a piece at the pre-clinical stage as an early-stage investor before March 26 to receive time-sensitive investor bonuses.

Invest in Cytonics Now

^{This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://cytonics.com/}

Now imagine using dollar-cost averaging (DCA): adding $500 every month for the next five years. This totals $30,000 invested from your pocket over 60 months. You naturally buy more shares on lower price days and fewer on higher ones, which helps keep your average cost balanced.

If XLF follows a similar historical pace around 7.4% annual growth, your monthly $500 contributions could grow your investment to about $35,900 by the end of five years. That means a gain of roughly $5,900 beyond what you put in — a solid 20% overall return from patient, regular investing.

Past performance doesn't guarantee the future — interest rates, economic cycles, or banking regulations can shift outcomes. But XLF offers broad exposure to major U.S. financial companies, capturing sector trends without picking individual stocks. Your $500 monthly plan is easy to maintain, letting compounding work quietly in the background.

The financial sector remains a core part of the economy with ongoing needs for lending and services. Staying consistent through any flatter periods is what usually leads to dependable long-term results.

Ready to keep this steady approach going?

There’s wisdom in simplicity—and nothing proves it more than the final guidance from Warren Buffett. After 60 years at the helm of Berkshire Hathaway, Buffett’s last message wasn’t about complex strategies, obscure metrics, or chasing the next “hot stock.” It was a blueprint: low-cost, broad, and patient investing.

He didn’t just suggest this approach—he bet on it publicly. In 2007, Buffett placed a $1 million wager that a simple S&P 500 index fund would outperform a basket of elite hedge funds over ten years. The results? The index returned 125.8%, while the hedge funds averaged 36.3%. A $3 annual fee beat millions in hedge fund expenses.

This isn’t theory. It’s evidence. And now, in 2026, the timing couldn’t be more relevant. Markets are at historically high valuations, with the S&P 500 Shiller CAPE ratio at 37.44—well above the long-term average of 16.04. Consumer sentiment is waning, unemployment creeping upward, and mega-cap growth stocks are facing AI investment fatigue. Value is outperforming growth, and Buffett’s principles are guiding the way.

VOO is the ultimate anchor. Low-cost, diversified, and time-tested, it gives exposure to America’s 500 largest companies at a fraction of the cost charged by Wall Street professionals.

Key points:

VOO captures the broad growth of the U.S. economy without requiring you to guess which stock will be next. It’s the baseline, the canvas upon which the other ETFs build—steady, predictable, and essential.

Growth isn’t everything, especially when valuations are stretched. VTV provides exposure to large-cap value stocks—companies trading for less than their intrinsic worth. Think financials, healthcare, energy, and industrials. These are the same sectors Buffett has relied on for decades.

Performance highlights:

VTV reflects Buffett’s philosophy: patience, discipline, and buying quality at a discount. Right now, it’s benefitting from what analysts are calling the Great Rotation—capital flowing from overvalued growth names into value, just as Buffett would expect.

A new report shows 44% of family offices are investing more in residential real estate. Now, you can access these assets with mogul. This platform lets you invest in properties producing +7% yields and 18% IRRs. Plus, they do all the property management for you.

Join 20,000 investors today.

Past performance isn't predictive; illustrative only. Investing risks principal; no securities offer. See important Disclaimers

For those prioritizing income, SCHD is a game-changer. It focuses on high-quality dividend-paying stocks with strong financials, sustainable cash flow, and consistent dividend growth.

2026 performance to date:

SCHD combines growth with income, creating a portfolio that generates money whether markets rise or fall. Its PE ratio is 16.2, making it relatively undervalued, and dividends compound over time, echoing the long-term approach Buffett has used with Coca-Cola and other stalwarts.

The beauty of these three ETFs lies in balance and simplicity:

Expense ratios across all three average just 0.04%, meaning a $100,000 portfolio costs about $40/year—an almost negligible cost compared to what financial advisors charge.

Allocation can vary by stage of life:

The math speaks for itself: $500 monthly invested at a 10% return grows to nearly $1 million in 30 years. For those with $200,000 already saved, shifting to this allocation could grow the portfolio to over $500,000 in 10 years, while dividends generate passive income exceeding $5,500/year.

Buffett’s final message is clear: extraordinary results don’t require extraordinary action. Automate, stay consistent, and let compounding do the heavy lifting.

This is the kind of framework that doesn’t chase headlines or hype. It quietly works, quietly compounds, and quietly beats the vast majority of active managers—even in turbulent markets. For the busy investor, it’s simple, disciplined, and profoundly effective.

The takeaway? Forget the noise. Focus on structure. Own the market. Tilt for value. Collect income. And let time reward patience.

Ready to Revolutionize Your Wealth?

Here's what's waiting for you:

As the world becomes increasingly digital, this question will be on the minds of millions seeking new income streams in 2026.

The answer is—Absolutely!

Thank you for taking the time to read today’s email! Your support is what allows me to send out this newsletter for free every day. 

 What do you think of the new format? Please provide your feedback in the poll below, and if you find the newsletter valuable, feel free to share it with other investors!

Disclaimer: This newsletter is for informational purposes only and should not be considered financial advice. Please consult with a financial advisor before making any investment decisions.